

JB


IFW

1637

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 5/9/06 Signature: Shari Jackson
(Shari Jackson)

Docket No.: CSHL-P02-010
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Hammond et al.

Confirmation No.: 4804

Application No.: 09/866557

Art Unit: 1637

Filed: May 24, 2001

Examiner: C. B. Wilder

For: METHODS AND COMPOSITIONS FOR
RNA INTERFERENCE

May 9, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

The subject application was withdrawn from issue on April 10, 2006. Prior to the receipt of the Notice of Allowance, Applicants had filed on August 9, 2005 a Request for Continued Examination (RCE). A first Office Action was not issued subsequent to the RCE. Accordingly, this Supplemental Information Disclosure Statement is being filed before the mailing date of the first Office Action after the filing of a RCE under 37 CFR §1.114 (37 CFR 1.97(b)(4)). In addition Examiner Andrew Wang of the United States Patent and Trademark Office advised the undersigned on May 9, 2006 that prosecution is being reopened and that the subject Information Disclosure Statement may be filed. Accordingly, Applicant hereby requests that the Information Disclosure Statement be considered.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such. The documents cited in this Supplemental Information Disclosure Statement are each cited by the Patent Office in Office Actions in related United States Patent Applications U.S. Serial No. 09/858,862, filed May 16, 2001, U.S. Serial No. 10/055,797, filed January 22, 2002, and U.S. Serial No. 10/350,798, filed January 24, 2003.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

No fee is deemed necessary in connection with this Supplemental Information Disclosure Statement. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. CSHL-P02-010. A duplicate copy of this paper is enclosed.

Dated: May 9, 2006

Respectfully submitted,

By 

Spencer H. Schneider

Registration No.: 45,923

ROPES & GRAY LLP


1251 Avenue of the Americas

New York, NY 10020-1105

(212) 596-9000

(212) 596-9090 (Fax)

Attorneys/Agents For Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/866557	
			Filing Date	May 24, 2001	
			First Named Inventor	Scott Hammond	
			Art Unit	1637	
			Examiner Name	C. B. Wilder	
			Attorney Docket Number	CSHL-P02-010	
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
	AA*	US-5,246,921		09-21-1993	Reddy et al.	
	AB*	US-5,998,148		12-07-1999	Bennett et al.	
	AC*	US-6,107,027		08-22-2000	Kay et al.	
	AD*	US-6,605,429		08-12-2003	Barber et al.	
	AE*	US-2004/0229266		11-18-2004	Tuschi et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
	BA	WO	94/01550	01-1994	Agrawal et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Elbashir et al., "Functional anatomy of siRNAs for mediating efficient RNAi in drosophila melanogaster embryo lysate" EMBO Journal, 20(23):6877-6888 (2001).	
	CB	Good et al., "Expression of small, therapeutic RNAs in human cell nuclei", Gene Therapy, 4:45-54 (1997).	
	CC	Lipardi et al., "RNAi as Random Degradative PCR: siRNA Primers Convert mRNA that are Degraded to Generate New siRNAs" Cell, 107:297-307 (2001).	
	CD	Mette et al., "Transcriptional silencing and promoter methylation triggered by double stranded RNA" The EMBO Journal, 19(19):5194-5201 (2000).	
	CE	Opalinska et al., "Nucleic acid based therapeutics basic principles and recent applications" Nature Reviews: Drug Discovery, 1:503-514 (2002)	
	CF	Zhang et al., "Targeted gene silencing by small interfering RNA based knock down technology" Curr. Pharma. Biotech, 5:1-7 (2004).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--